Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis.
There is considerable evidence for a relationship between hemostasis and malignancy. Since platelet adhesion to tumor cells has been implicated in the metastatic process and plasma levels of fibrinogen (Fg) and soluble fibrin (sFn) monomer are increased in cancer, we hypothesized that these molecules might enhance tumor-platelet interaction. We therefore studied binding of sFn monomer to tumor cells in a static microplate adhesion assay and determined the effect of pre-treating tumor cells with sFn on tumor cell-induced thrombocytopenia and experimental metastasis. Soluble fibrin (produced by adding thrombin to FXIII- and plasminogen-free Fg in the presence of Gly-Pro-Arg-Pro-amide (GPRP-NH2) significantly increased platelet adherence to tumor cells. This effect was primarily mediated by the integrins alphaIIb beta3 on the platelet and CD 54 (ICAM-1) on the tumor cells. Platelets adhered to untreated A375 cells (28 +/- 8 platelets/tumor cell) and this was not significantly affected by pre-treatment of the tumor cells with fibrinogen or GPRP-NH2. Although thrombin treatment increased adherence, pre-incubation of the tumor cells with sFn resulted in a further increase in platelet binding to tumor cells. In contrast to untreated tumor cells, intravenous injection of sFn-treated A 375 cells reduced the platelet count in anticoagulated mice, supporting the in vitro finding that sFn enhanced tumor cell-platelet adherence. In a more aggressive model of experimental metastasis, treating tumor cells with sFn enhanced lung seeding by 65% compared to untreated cells. Extrapolation of our data to the clinical situation suggests that coagulation activation, and subsequent increase in circulating Fn monomer, may enhance platelet adhesion to circulating tumor cells and thereby facilitate metastatic spread.
Research and Clinical Laboratories, Walt Disney Memorial Cancer Institute at Florida Hospital, Orlando 32804, USA. John_Biggerstaff@mail.fhmis.net
J P
JP
Biggerstaff
N
N
Seth
A
A
Amirkhosravi
M
M
Amaya
S
S
Fogarty
T V
TV
Meyer
F
F
Siddiqui
J L
JL
Francis
D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis; D016824:Antigens, Human Platelet / Q000096:biosynthesis; D012103:Batroxobin / Q000494:pharmacology; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects; D002448:Cell Adhesion / Q000502:physiology; D002450:Cell Communication / Q000502:physiology; D005260:Female; D005337:Fibrin / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D005343:Fibrinolytic Agents / Q000494:pharmacology; D005434:Flow Cytometry; D006490:Hemostatics / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D018328:Melanoma, Amelanotic / Q000150:complications / Q000378:metabolism / Q000473:pathology* / Q000556:secondary; D051379:Mice; D008819:Mice, Nude; D010973:Platelet Adhesiveness / Q000187:drug effects / Q000502:physiology*; D018179:Receptors, Thrombin / Q000378:metabolism; D012995:Solubility; D013917:Thrombin / Q000378:metabolism / Q000494:pharmacology; D013921:Thrombocytopenia / Q000188:drug therapy / Q000209:etiology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D015703:Antigens, CD; D016824:Antigens, Human Platelet; D005343:Fibrinolytic Agents; D006490:Hemostatics; D018179:Receptors, Thrombin; C083451:human platelet antigen 1b; D005337:Fibrin; D012103:Batroxobin; D013917:Thrombin